Yuanhui Liu1,2, Zhihua Huang1,3,2, Kaizhuang Huang1,3, Guang Li1, Jianfang Luo1, Ying Xu4, Pingyan Chen4, Jiyan Chen1, Ling Wang1. 1. Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 2. Co-first authors. 3. Shantou University Medical College, Shantou, China. 4. Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.
Abstract
STUDY OBJECTIVES: Natriuretic peptides have been identified as biomarkers of increased myocardial wall stress in the context of obstructive sleep apnea (OSA) in the general population. However, the relationship between N-terminal pro B-type natriuretic peptide (NT-proBNP) and OSA remains unclear in patients with coronary artery disease (CAD). Hence, we aimed to investigate the clinical value of NT-proBNP in evaluating OSA in a large population of patients with CAD. METHODS: Consecutive patients with CAD were prospectively enrolled between February 2015 and March 2018. Portable respiratory monitoring was applied to facilitate the diagnosis of sleep apnea. Patients were as assigned to the non-OSA (when the respiratory events index [REI] or 3% oxygen desaturation index [ODI] < 15 events/h) and OSA (when the REI or 3% ODI ≥ 15 events/h) groups. Multivariate analyses were used to explore the independent association between NT-proBNP levels and OSA. RESULTS: A total of 1,292 consecutive patients were included with a mean NT-proBNP value of 826.57 μg/L. Patients with high levels of NT-proBNP experienced increasing severity of OSA in those with CAD (P = .0004). Univariate analysis demonstrated that NT-proBNP was a risk factor for OSA (odds ratio [OR] 1.10, 95% confidence interval [CI] 1.03-1.18, P = .005). In addition, multivariate analysis revealed that NT-proBNP was independently associated with the presence of OSA (OR 1.11, 95% CI 1.02-1.20, P = .012) even after adjusting for other cofounding factors. CONCLUSIONS: Elevated levels of NT-proBNP were independently associated with a higher likelihood of OSA in patients with CAD. Periodically screening for NT-proBNP levels may provide early identification of OSA.
STUDY OBJECTIVES: Natriuretic peptides have been identified as biomarkers of increased myocardial wall stress in the context of obstructive sleep apnea (OSA) in the general population. However, the relationship between N-terminal pro B-type natriuretic peptide (NT-proBNP) and OSA remains unclear in patients with coronary artery disease (CAD). Hence, we aimed to investigate the clinical value of NT-proBNP in evaluating OSA in a large population of patients with CAD. METHODS: Consecutive patients with CAD were prospectively enrolled between February 2015 and March 2018. Portable respiratory monitoring was applied to facilitate the diagnosis of sleep apnea. Patients were as assigned to the non-OSA (when the respiratory events index [REI] or 3% oxygen desaturation index [ODI] < 15 events/h) and OSA (when the REI or 3% ODI ≥ 15 events/h) groups. Multivariate analyses were used to explore the independent association between NT-proBNP levels and OSA. RESULTS: A total of 1,292 consecutive patients were included with a mean NT-proBNP value of 826.57 μg/L. Patients with high levels of NT-proBNP experienced increasing severity of OSA in those with CAD (P = .0004). Univariate analysis demonstrated that NT-proBNP was a risk factor for OSA (odds ratio [OR] 1.10, 95% confidence interval [CI] 1.03-1.18, P = .005). In addition, multivariate analysis revealed that NT-proBNP was independently associated with the presence of OSA (OR 1.11, 95% CI 1.02-1.20, P = .012) even after adjusting for other cofounding factors. CONCLUSIONS: Elevated levels of NT-proBNP were independently associated with a higher likelihood of OSA in patients with CAD. Periodically screening for NT-proBNP levels may provide early identification of OSA.
Authors: Virend K Somers; David P White; Raouf Amin; William T Abraham; Fernando Costa; Antonio Culebras; Stephen Daniels; John S Floras; Carl E Hunt; Lyle J Olson; Thomas G Pickering; Richard Russell; Mary Woo; Terry Young Journal: J Am Coll Cardiol Date: 2008-08-19 Impact factor: 24.094
Authors: Kristian Thygesen; Johannes Mair; Christian Mueller; Kurt Huber; Michael Weber; Mario Plebani; Yonathan Hasin; Luigi M Biasucci; Evangelos Giannitsis; Bertil Lindahl; Wolfgang Koenig; Marco Tubaro; Paul Collinson; Hugo Katus; Marcello Galvani; Per Venge; Joseph S Alpert; Christian Hamm; Allan S Jaffe Journal: Eur Heart J Date: 2011-02-02 Impact factor: 29.983
Authors: Shahrokh Javaheri; Ferran Barbe; Francisco Campos-Rodriguez; Jerome A Dempsey; Rami Khayat; Sogol Javaheri; Atul Malhotra; Miguel A Martinez-Garcia; Reena Mehra; Allan I Pack; Vsevolod Y Polotsky; Susan Redline; Virend K Somers Journal: J Am Coll Cardiol Date: 2017-02-21 Impact factor: 24.094
Authors: Richard B Berry; Rohit Budhiraja; Daniel J Gottlieb; David Gozal; Conrad Iber; Vishesh K Kapur; Carole L Marcus; Reena Mehra; Sairam Parthasarathy; Stuart F Quan; Susan Redline; Kingman P Strohl; Sally L Davidson Ward; Michelle M Tangredi Journal: J Clin Sleep Med Date: 2012-10-15 Impact factor: 4.062
Authors: Joshua D Gottlieb; Alan R Schwartz; Joanne Marshall; Pamela Ouyang; Linda Kern; Veena Shetty; Maria Trois; Naresh M Punjabi; Cynthia Brown; Samer S Najjar; Stephen S Gottlieb Journal: J Am Coll Cardiol Date: 2009-10-27 Impact factor: 24.094